Merck stock holds on dividend and pipeline updates

Merck & Co. (ISIN US58933Y1055) is supported by 2025 revenue of $64.2 billion and diluted EPS of $8.98, with the quarterly dividend lifted to $0.81 per share. Those figures frame the stock as investors weigh cash generation against the next phase of pipeline execution.

2025 revenue and EPS

Merck reported 2025 revenue of $64.2 billion, compared with $60.1 billion in 2024, which marks a year-over-year increase of about 6.8%. Diluted EPS for 2025 reached $8.98, up from $1.48 in 2024, according to the companys latest annual reporting context.

The scale of the profit improvement matters because the comparison is not cosmetic: the gap between $8.98 and $1.48 shows how much the earnings base shifted in 2025. For investors, that makes the quality of the companys current margin profile more important than a one-day market move.

Dividend raised to $0.81

Merck also raised its quarterly dividend to $0.81 per share, and the annualized payout now implies $3.24 per share if maintained for four quarters. That is a concrete capital-return signal, and it is especially relevant after a year in which earnings expanded faster than revenue.

Against that backdrop, the dividend increase sits alongside a 2025 revenue base of $64.2 billion and diluted EPS of $8.98, giving the stock a clear mix of operating scale and shareholder cash return. The comparison between 2024 and 2025 reinforces the point: earnings moved much faster than sales.

Pipeline focus remains central

Mercks product portfolio still matters because the market tends to value durability in oncology, vaccines, and specialty medicines more than any single quarter. The companys annual reporting context shows that the business is large enough to absorb pipeline volatility, but it still needs fresh product momentum to sustain earnings power.

A first. The dividend and annual profit figures are already visible, but the longer-term valuation case depends on how consistently Merck converts research spending into commercial launches and label expansions.

Key product line

Keytruda remains the companys most important reference product in many investor discussions, because it is central to Mercks oncology franchise and to the markets view of durability in future revenue streams. Even when broader company figures are the headline, this product line is still the clearest read-through for sentiment around the pipeline.

That is why the 2025 financial base matters: revenue of $64.2 billion and diluted EPS of $8.98 provide the operating backdrop for any discussion of future oncology growth. The companys latest annual figures show that the stock story is not just about one product, but the concentration risk around the product mix remains visible.

Stock level context

Merck stock is trading against a background of large-cap pharmaceutical stability rather than high-volatility story stock behavior. The current article uses the latest company-reported 2025 figures and dividend data to frame the investment case because no dated market quote is available in this call.

Merck & Co. is a New York-listed pharmaceutical company with its latest reported 2025 revenue at $64.2 billion and diluted EPS at $8.98. The quarterly dividend stands at $0.81 per share, or $3.24 annualized if unchanged for a full year.